glp-1 telehealth crackdown news today Is Changing Fast The growing availability of compounded

Discontinuation of GLP-1 medications typically results in predictable physiological changes as the pharmacological effects wear off

however, the type, severity, and frequency of these effects may differ between agents, formulations, and dosing schedules

According to the Cleveland Clinic, the higher the dose of the GLP-1 agonist, the more extreme the effects

doi:10.1016/j.endmts.2020.100059 97

the Judicial Panel on Multidistrict Litigation added Saxenda to MDL 3094 in December 2024, expanding the scope to include this earlier-generation GLP-1 medication The consolidation of these medications into a single MDL proceedings streamlines the litigation process while allowing each plaintiff to maintain their individual claim for damages

Ultimately, many organizations are moving beyond a single yes or no coverage decision